Survival rates in pancreatic cancer linked to inverse correlation between specific oncogene and tumor suppressant
A new Tel Aviv University study pinpoints the inverse correlation between a known oncogene — a gene that promotes the development of cancer — and the expression of an oncosuppressor microRNA as the reason for extended pancreatic cancer survival. The study may serve as a basis for the development of an effective cocktail of drugs for this deadly disease and other cancers.
The study, which was published in Nature Communications, was led by Prof. Ronit Satchi-Fainaro, Chair of the Department of Physiology and Pharmacology at TAU’s Sackler Faculty of Medicine, and conducted by Hadas Gibori and Dr. Shay Eliyahu, both of Prof. Satchi-Fainaro’s multidisciplinary laboratory, in collaboration with Prof. Eytan Ruppin of TAU’s Computer Science Department and the University of Maryland and Prof. Iris Barshack and Dr. Talia Golanof Chaim Sheba Medical Center, Tel Hashomer.
Pancreatic cancer is among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients die within just a year of diagnosis. “Despite all the treatments afforded by modern medicine, some 75% of all pancreatic cancer patients die within 12 months of diagnosis, including many who die within just a few months,” Prof. Satchi-Fainaro says.
“But around seven percent of those diagnosed will survive more than five years. We sought to examine what distinguishes the survivors from the rest of the patients,” Prof. Satchi-Fainaro continues. “We thought that if we could understand how some people live several years with this most aggressive disease, we might be able to develop a new therapeutic strategy.”
Calling a nano-taxi
The research team examined pancreatic cancer cells and discovered an inverse correlation between the signatures of miR-34a, a tumor suppressant, and PLK1, a known oncogene. The levels of miR-34a were low in pancreatic cancer mouse models, while the levels of the oncogene were high. This correlation made sense for such an aggressive cancer. But the team needed to see if the same was true in humans.
The scientists performed RNA profiling and analysis of samples taken from pancreatic cancer patients. The molecular profiling revealed the same genomic pattern found earlier in mouse models of pancreatic cancer.
The scientists then devised a novel nanoparticle that selectively delivers genetic material to a tumor and prevents side effects in surrounding healthy tissues.
“We designed a nanocarrier to deliver two passengers: (1) miR-34a, which degrades hundreds of oncogenes; and (2) a PLK1 small interfering RNA (siRNA), that silences a single gene,” Prof. Satchi-Fainaro says. “These were delivered directly to the tumor site to change the molecular signature of the cancer cells, rendering the tumor dormant or eradicating it altogether.
“The nanoparticle is like a taxi carrying two important passengers,” Prof. Satchi-Fainaro continues. “Many oncology protocols are cocktails, but the drugs usually do not reach the tumor at the same time. But our ‘taxi’ kept the ‘passengers’ — and the rest of the body — safe the whole way, targeting only the tumor tissue. Once it ‘parked,’ an enzyme present in pancreatic cancer caused the carrier to biodegrade, allowing the therapeutic cargo to be released at the correct address — the tumor cells.”
Improving the odds
To validate their findings, the scientists injected the novel nanoparticles into pancreatic tumor-bearing mice and observed that by balancing these two targets — bringing them to a normal level by increasing their expression or blocking the gene responsible for their expression — they significantly prolonged the survival of the mice.
“This treatment takes into account the entire genomic pattern, and shows that affecting a single gene is not enough for the treatment of pancreatic cancer or any cancer type in general,” according to Prof. Satchi-Fainaro.
The Latest on: Pancreatic cancer
- Creative Biolabs Provides Abundant Recombinant Antibody Products Targeting at the Pancreatic Canceron September 6, 2019 at 3:55 pm
Pancreatic cancer, ranking third in cancer-related deaths in the United States, has been taken as one of the malignant tumors of the digestive system, marked with strong invasiveness, high degree of ...
- Harvard Study Say Cannabis May Help Fight Pancreatic Canceron September 6, 2019 at 5:19 am
Scientific evidence is beginning to mount that cannabis may prove beneficial in the fight against cancer. The latest comes from a Harvard University study involving cannabis flavonoids and pancreatic ...
- New medicine may enhance the effect of chemotherapy on pancreatic canceron September 5, 2019 at 5:08 am
One of the major obstacles in the treatment of pancreatic cancer is the defense wall that is formed around the tumor. This "desmoplastic stroma" prevents chemotherapy from reaching the tumor.
- Health watch: A new way to treat pancreatic canceron September 4, 2019 at 10:06 pm
Over the past few years, there's been increased awareness of pancreatic cancer with the deaths of actor Patrick Swayze, and Apple co-founder Steve Jobs. Right now, jeopardy host Alex Trebek is ...
- Here's Why Pancreatic Cancer Is Hard To Treaton September 4, 2019 at 9:57 pm
As one of the most deadly cancers plaguing us today, it’s unfortunate that pancreatic cancer is still nearly impossible to treat or cure. In a world where chemotherapy and other forms of treatment are ...
- Study confirms protein as potential cause of most common type of pancreatic canceron September 4, 2019 at 2:01 pm
Researchers at The University of Texas MD Anderson Cancer Center have confirmed a protein as an oncogene responsible for the most common and lethal form of pancreatic cancer known as pancreatic ...
- Did a 15-Year-Old Invent a ‘100% Accurate’ Pancreatic Cancer Test?on September 4, 2019 at 9:18 am
Jack Andraka, 15, came up with a “100 percent accurate” cancer-detection method that was “168 times faster, 26,000 times less expensive, and 400 times more sensitive” than current methods. Though his ...
- Drug developed to treat metastatic pancreatic cancer may help prolong lifeon September 4, 2019 at 6:00 am
A drug developed by researchers at the Renaissance School of Medicine at Stony Brook University that targets enzymes involved in the development of pancreatic cancer cells is showing promise for ...
- Pancreatic cancer tumors attack the blood vessels that deliver chemo drugson September 4, 2019 at 4:12 am
Pancreatic cancer is nearly impossible to treat. New research now shows this may be because its tumors destroy the surrounding blood vessels that doctors typically rely on to deliver anti-cancer drugs ...
- Pancreatic Cancer Action Network Appoints Columbia Sportswear Executive Lisa Kulok To Board Of Directorson September 4, 2019 at 3:00 am
MANHATTAN BEACH, Calif., Sept. 4, 2019 /PRNewswire/ -- The Pancreatic Cancer Action Network (PanCAN), a leading patient advocacy organization, announced today that Columbia Sportswear executive Lisa ...
via Google News and Bing News